person · Reporting owner

Arkowitz David

Disclosed activity across 5 companies

Tapewire entity: 72639
SEC CIK: 0001296999

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Flexion Therapeutics IncFLXN · Entity 16545	Chief Financial Officer	May 10, 2021	May 12, 2021
Seres Therapeutics, Inc.MCRB · Entity 7191	Chief Financial Officer	February 14, 2024	February 16, 2024
iBio, Inc.IBIO · Entity 6906	Director	November 20, 2025	November 24, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Flexion Therapeutics Inc

Report date May 10, 2021 · Filed May 12, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	220,719	Reported balance After 2021-05-10 transaction · row 1 1 source row Row 1 · 2021-05-10 · Sale · Disposed 2,229 · Balance 220,719 F1: Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018. F2: The weighted average sale price for the transaction reported was $7.23. The shares were sold at a range of prices between $7.14 and $7.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Filing footnotes · ownership attribution and instrument terms

F1: Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018.

F2: The weighted average sale price for the transaction reported was $7.23. The shares were sold at a range of prices between $7.14 and $7.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Seres Therapeutics, Inc.

Report date February 14, 2024 · Filed February 16, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	182,442	Ending reported balance After 2024-02-16 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-02-15 · Exercise / conversion · Acquired 10,625 · Balance 186,381 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2024-02-16 · Sale · Disposed 3,939 · Balance 182,442 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2034-02-13	Direct	213,750	Reported balance After 2024-02-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-14 · Grant · Acquired 213,750 · Balance 213,750 F4: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2034-02-13	Direct	287,905	Reported balance After 2024-02-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-14 · Grant · Acquired 287,905 · Balance 287,905 F5: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	35,625	Reported balance After 2024-02-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-14 · Grant · Acquired 35,625 · Balance 35,625 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	31,875	Reported balance After 2024-02-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-15 · Exercise / conversion · Disposed 10,625 · Balance 31,875 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

F3: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

F5: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.

F6: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

F7: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

iBio, Inc.

Report date November 20, 2025 · Filed November 24, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-11-19	Direct	13,500	Reported balance After 2025-11-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-11-20 · Grant · Acquired 13,500 · Balance 13,500 F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

F-star Therapeutics, Inc.

Report date November 20, 2020 · Filed March 09, 2023

Section 16 reporting ended · disclosed 2023-03-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-03-08 transaction · row 1 1 source row Row 1 · 2023-03-08 · Other · Disposed 8,386 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2: (Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2031-06-04	Direct	Reported balance After 2023-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2032-06-17	Direct	Reported balance After 2023-03-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.28 · Expires 2025-03-30	Direct	Reported balance After 2020-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-20 · Other · Disposed 10,000 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2026-07-27	Direct	Reported balance After 2020-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 · Expires 2027-06-14	Direct	Reported balance After 2020-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2028-06-17	Direct	Reported balance After 2020-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2029-07-09	Direct	Reported balance After 2020-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23	Direct	Reported balance After 2020-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2021-11-23	Direct	Reported balance After 2020-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-20 · Other · Disposed 4,386 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F2: (Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)).

F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option.

F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.

F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.

KINETA, INC./DE

Report date June 30, 2025 · Filed July 02, 2025

Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-06-30 transaction · row 1 1 source row Row 1 · 2025-06-30 · Disposition to issuer · Disposed 16,571 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3: The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022. F4: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28	Direct	Reported balance After 2025-06-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F5: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28	Direct	Reported balance After 2025-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-30 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F5: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").

F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.

F3: The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022.

F4: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.

F5: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2025 Filed Nov 24, 2025 21:05 UTC	iBio, Inc. IBIO · Entity 6906	GrantStock Option (right to buy) · Derivative	13,500	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001104659-25-115407 · tm2532045-1_4seq1.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-11-19 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document
June 30, 2025 Filed Jul 2, 2025 16:21 UTC	KINETA, INC./DE KANT · Entity 77778	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.28	$0.00	Disclosure SEC source: 0000950170-25-092994 · ownership.xml · derivative · entry 3 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F5 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. F5 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. Read SEC document
June 30, 2025 Filed Jul 2, 2025 16:21 UTC	KINETA, INC./DE KANT · Entity 77778	Disposition to issuerStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $3.28	$0.00	Disclosure SEC source: 0000950170-25-092994 · ownership.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F5 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. F5 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. Read SEC document
June 30, 2025 Filed Jul 2, 2025 16:21 UTC	KINETA, INC./DE KANT · Entity 77778	Disposition to issuerCommon Stock	16,571	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-092994 · ownership.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3 · shares: The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022. F4 · price: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. Read SEC document
June 25, 2025 Filed Jun 25, 2025 21:49 UTC	KINETA, INC./DE KANT · Entity 77778	GrantCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-090137 · ownership.xml · nonDerivative · entry 3 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,141 Read SEC document
June 23, 2025 Filed Jun 25, 2025 21:49 UTC	KINETA, INC./DE KANT · Entity 77778	Exercise / conversionStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $0.61	$0.00	Disclosure SEC source: 0000950170-25-090137 · ownership.xml · derivative · entry 4 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Read SEC document
June 23, 2025 Filed Jun 25, 2025 21:49 UTC	KINETA, INC./DE KANT · Entity 77778	Tax withholdingCommon Stock	4,706	$0.26	$1,223.56	Disclosure SEC source: 0000950170-25-090137 · ownership.xml · nonDerivative · entry 2 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,141 Read SEC document
June 23, 2025 Filed Jun 25, 2025 21:49 UTC	KINETA, INC./DE KANT · Entity 77778	Exercise / conversionCommon Stock	12,500	$0.61	$7,637.50	Disclosure SEC source: 0000950170-25-090137 · ownership.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:32 UTC	iBio, Inc. IBIO · Entity 6906	PurchaseCommon Stock	18,382	$2.72	$49,999.04	Disclosure SEC source: 0001104659-25-003061 · tm253156-4_4seq1.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,382 F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025. Read SEC document
November 21, 2024 Filed Nov 25, 2024 21:31 UTC	iBio, Inc. IBIO · Entity 6906	GrantStock Option (right to buy) · Derivative	12,600	$0.00 Strike: $2.45	$0.00	Disclosure SEC source: 0001104659-24-122589 · tm2429436-2_4seq1.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 12,600 shares Expires 2034-11-20 F1 · security: These options vest pro rata on a monthly basis over three years commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over three years commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over three years commencing on the date of the grant. Read SEC document
September 04, 2024 Filed Sep 5, 2024 16:18 UTC	KINETA, INC./DE KA · Entity 77778	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $0.61	$0.00	Disclosure SEC source: 0000950170-24-104011 · ownership.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-09-03 F1 · derivative.exercise_date: The stock option will vest in equal quarterly installments over one year following June 21, 2024, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
February 16, 2024 Filed Feb 16, 2024 21:13 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	SaleCommon Stock	3,939	$1.08	$4,254.12	Disclosure SEC source: 0000950170-24-016687 · ownership.xml · nonDerivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,442 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 15, 2024 Filed Feb 16, 2024 21:13 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	Exercise / conversionRestricted Stock Units · Derivative	10,625	$0.00	$0.00	Disclosure SEC source: 0000950170-24-016687 · ownership.xml · derivative · entry 6 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 10,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document
February 15, 2024 Filed Feb 16, 2024 21:13 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	Exercise / conversionCommon Stock	10,625	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-016687 · ownership.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:13 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantRestricted Stock Units · Derivative	35,625	$0.00	$0.00	Disclosure SEC source: 0000950170-24-016687 · ownership.xml · derivative · entry 5 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,625 Underlying: Common Stock · 35,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:13 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (Right to Buy) · Derivative	287,905	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0000950170-24-016687 · ownership.xml · derivative · entry 4 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,905 Underlying: Common Stock · 287,905 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:13 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (Right to Buy) · Derivative	213,750	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0000950170-24-016687 · ownership.xml · derivative · entry 3 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,750 Underlying: Common Stock · 213,750 shares Expires 2034-02-13 F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document
October 30, 2023 Filed Oct 31, 2023 21:39 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	SaleCommon Stock	4,066	$1.35	$5,489.10	Disclosure SEC source: 0000899243-23-020077 · doc4.xml · nonDerivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,756 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 21, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.365, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 27, 2023 Filed Oct 31, 2023 21:39 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	Exercise / conversionRestricted Stock Units · Derivative	13,209	$0.00	$0.00	Disclosure SEC source: 0000899243-23-020077 · doc4.xml · derivative · entry 4 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,209 Underlying: Common Stock · 13,209 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document
October 27, 2023 Filed Oct 31, 2023 21:39 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	Exercise / conversionCommon Stock	13,209	$0.00	$0.00	Disclosure SEC source: 0000899243-23-020077 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. Read SEC document
April 27, 2023 Filed May 1, 2023 16:43 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantCommon stock	42,500	$0.00	$0.00	Disclosure SEC source: 0000899243-23-011944 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,613 F1 · kind: On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 42,500 shares. F2 · balance_after: Includes 11,121 shares of common stock acquired under the Issuer's employee stock purchase plan. Read SEC document
April 27, 2023 Filed Oct 31, 2023 21:39 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantRestricted Stock Units · Derivative	26,418	$0.00	$0.00	Disclosure SEC source: 0000899243-23-020077 · doc4.xml · derivative · entry 3 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,418 Underlying: Common Stock · 26,418 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document
April 12, 2023 Filed Apr 14, 2023 16:06 UTC	KINETA, INC./DE KA · Entity 77778	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $3.28	$0.00	Disclosure SEC source: 0001209191-23-024288 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-04-11 F2 · derivative.exercise_date: The stock option will vest as to 1/12 of the total number of shares on July 7, 2023 and each monthly anniversary thereafter, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
April 12, 2023 Filed Apr 14, 2023 16:06 UTC	KINETA, INC./DE KA · Entity 77778	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.28	$0.00	Disclosure SEC source: 0001209191-23-024288 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-04-11 F1 · derivative.exercise_date: The stock option vested and continues to vest as to 1/36 of the total number of shares on February 1, 2023 and on each monthly anniversary thereafter, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
March 08, 2023 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	Disposition to issuerStock Option (right to buy) · Derivative	20,000	Not disclosed Strike: $3.41	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 3 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F3 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · kind: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · kind: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · price: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · price: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · derivative.exercise_date: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · derivative.exercise_date: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. Read SEC document
March 08, 2023 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	Disposition to issuerStock Option (right to buy) · Derivative	20,000	Not disclosed Strike: $6.88	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-06-04 F3 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · kind: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · kind: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · price: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · price: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4 · derivative.exercise_date: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5 · derivative.exercise_date: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. Read SEC document
March 08, 2023 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	OtherCommon Stock	8,386	$7.12	$59,708.32	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2 · kind: (Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020. F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2 · price: (Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020. Read SEC document
February 03, 2023 Filed Feb 7, 2023 17:44 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (Right to Buy) · Derivative	85,000	$0.00 Strike: $5.50	$0.00	Disclosure SEC source: 0000899243-23-004204 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-02-02 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document
February 03, 2023 Filed Feb 7, 2023 17:44 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantRestricted Stock Units · Derivative	42,500	$0.00	$0.00	Disclosure SEC source: 0000899243-23-004204 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document
October 27, 2022 Filed Oct 31, 2022 18:05 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantCommon stock	42,500	$0.00	$0.00	Disclosure SEC source: 0000899243-22-034577 · doc4.xml · nonDerivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,992 F1 · kind: On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 42,500 shares. Read SEC document
July 05, 2022 Filed Jul 6, 2022 19:23 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantCOMMON STOCK	63,492	$3.15	$199,999.80	Disclosure SEC source: 0000899243-22-025516 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 Read SEC document
June 17, 2022 Filed Jun 22, 2022 17:06 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	GrantStock Option · Derivative	20,000	$0.00 Strike: $3.41	$0.00	Disclosure SEC source: 0001209191-22-038712 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F1 · shares: These options were granted under the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the Reporting Person's continued service as a director of the company. Read SEC document
June 15, 2022 Filed Oct 31, 2022 18:05 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-034577 · doc4.xml · derivative · entry 3 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: On June 1, 2021, the reporting person was granted an award of restricted stock units, 100% of which vested and settled on June 15, 2022. F3 · derivative.expiration_date: On June 1, 2021, the reporting person was granted an award of restricted stock units, 100% of which vested and settled on June 15, 2022. Read SEC document
June 15, 2022 Filed Oct 31, 2022 18:05 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	Exercise / conversionCommon stock	5,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-034577 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:30 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (Right to Buy) · Derivative	190,000	$0.00 Strike: $7.38	$0.00	Disclosure SEC source: 0000899243-22-005316 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document
June 04, 2021 Filed Jun 7, 2021 16:03 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	GrantStock Option · Derivative	20,000	$0.00 Strike: $6.88	$0.00	Disclosure SEC source: 0001209191-21-038552 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-04 F1 · shares: These options were granted under the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 4, 2022, subject to the Reporting Person's continued service as a director of the company. Read SEC document
June 02, 2021 Filed Jun 4, 2021 16:05 UTC	KINETA, INC./DE YMTX · Entity 77778	GrantStock Option (Right to Buy) · Derivative	14,800	$0.00 Strike: $15.26	$0.00	Disclosure SEC source: 0000899243-21-022014 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Underlying: Common Stock · 14,800 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021. Read SEC document
June 01, 2021 Filed Jun 1, 2021 21:25 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-021446 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest and settle on June 15, 2022. The restricted stock units have no expiration date. F3 · derivative.expiration_date: 100% of the restricted stock units will vest and settle on June 15, 2022. The restricted stock units have no expiration date. Read SEC document
June 01, 2021 Filed Jun 1, 2021 21:25 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Options (right to buy) · Derivative	270,000	$0.00 Strike: $20.19	$0.00	Disclosure SEC source: 0000899243-21-021446 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option will vest and become exercisable as to 25% of the shares on June 1, 2022. The remainder of the shares will vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document
May 10, 2021 Filed May 12, 2021 17:06 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	SaleCommon Stock	2,229	$7.23	$16,115.67	Disclosure SEC source: 0001209191-21-032103 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,719 F1 · kind: Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018. F2 · price: The weighted average sale price for the transaction reported was $7.23. The shares were sold at a range of prices between $7.14 and $7.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
March 01, 2021 Filed Mar 3, 2021 18:26 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	20,000	$0.00 Strike: $11.41	$0.00	Disclosure SEC source: 0001209191-21-017248 · doc4.xml · derivative · entry 3 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-28 F2 · derivative.exercise_date: 25% of the shares shall vest on the one-year anniversary of January 1, 2021 (the "Vesting Commencement Date"), and thereafter 1/48th of the total shares shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four years after the Vesting Commencement Date. Read SEC document
March 01, 2021 Filed Mar 3, 2021 18:26 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantCommon Stock	41,900	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017248 · doc4.xml · nonDerivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,948 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document
March 01, 2021 Filed Mar 3, 2021 18:26 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017248 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,048 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document
January 05, 2021 Filed Jan 7, 2021 17:50 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	SaleCommon Stock	6,073	$11.13	$67,592.49	Disclosure SEC source: 0001209191-21-002558 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,048 F1 · kind: Sale of shares to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on March 1, 2019, and March 2, 2020. F2 · price: The weighted average sale price for the transaction reported was $11.13. The shares were sold at a range of prices between $11.12 and $11.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
December 22, 2020 Filed Dec 28, 2020 19:05 UTC	KINETA, INC./DE YMTX · Entity 77778	GrantCommon Stock	4,347	$23.00	$99,981.00	Disclosure SEC source: 0000899243-20-035260 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,347 Read SEC document
November 20, 2020 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	OtherStock Option (right to buy) · Derivative	7,500	Not disclosed Strike: $1.60	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 10 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2030-06-23 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document
November 20, 2020 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	OtherStock Option (right to buy) · Derivative	7,500	Not disclosed Strike: $4.62	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 9 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2029-07-09 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document
November 20, 2020 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	OtherStock Option (right to buy) · Derivative	5,500	Not disclosed Strike: $13.99	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 8 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2028-06-17 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document
November 20, 2020 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	OtherStock Option (right to buy) · Derivative	5,500	Not disclosed Strike: $14.27	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 7 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2027-06-14 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document
November 20, 2020 Filed Mar 9, 2023 09:10 UTC	F-star Therapeutics, Inc. FSTX · Entity 115726	OtherWarrant (right to buy) · Derivative	4,386	Not disclosed Strike: $10.79	Not disclosed	Disclosure SEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 6 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,386 shares Expires 2021-11-23 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.